{"id":21681,"date":"2025-01-16T17:13:05","date_gmt":"2025-01-16T09:13:05","guid":{"rendered":"https:\/\/flcube.com\/?p=21681"},"modified":"2025-01-16T17:13:53","modified_gmt":"2025-01-16T09:13:53","slug":"chipscreens-epidaza-patent-faces-invalidation-request-review","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21681","title":{"rendered":"Chipscreen’s Epidaza Patent Faces Invalidation Request Review"},"content":{"rendered":"\n

China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321<\/a>) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection of intellectual property rights in the pharmaceutical sector. <\/p>\n\n\n\n

Patent Details<\/strong>
The patent in question, titled \u201cAn E-configured benzamide compound and its pharmaceutical formulation and application\u201d (Patent No.: ZL201410136761.X), was authorized by CNIPA in May 2017 and is valid through April 4, 2034. This patent covers the innovative compound and formulation of chidamide, a first-in-class subtype-selective histone deacetylase inhibitor.<\/p>\n\n\n\n

Chidamide’s Market Approvals<\/strong>
Chipscreen\u2019s chidamide has achieved three indication approvals in China for the treatment of peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma. The drug is also registered in Taiwan for the treatment of breast cancer and in Japan for use in leukemia and peripheral T-cell lymphoma. These approvals highlight the drug’s therapeutic potential and market reach in the Asia-Pacific region.<\/p>\n\n\n\n

Strategic Implications<\/strong>
The acceptance of the patent invalidation request for review by CNIPA underscores the importance of robust intellectual property protection in the pharmaceutical industry. For Chipscreen, this review process is crucial in maintaining the exclusivity and commercial viability of chidamide. The outcome of this review could have significant implications for the company’s market position and future development plans.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request…<\/p>\n","protected":false},"author":1,"featured_media":21682,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[61],"tags":[16,661,659,73,1240],"class_list":["post-21681","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legal-ip","tag-cancer","tag-chia-tai-tianqing-pharmaceutical","tag-chipscreen-biosciences","tag-patents","tag-sha-688321"],"yoast_head":"\nChipscreen's Epidaza Patent Faces Invalidation Request Review - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection of intellectual property rights in the pharmaceutical sector.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21681\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chipscreen's Epidaza Patent Faces Invalidation Request Review\" \/>\n<meta property=\"og:description\" content=\"China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection of intellectual property rights in the pharmaceutical sector.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21681\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-16T09:13:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-16T09:13:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1601.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"549\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chipscreen’s Epidaza Patent Faces Invalidation Request Review\",\"datePublished\":\"2025-01-16T09:13:05+00:00\",\"dateModified\":\"2025-01-16T09:13:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1601.png\",\"keywords\":[\"Cancer\",\"Chia Tai Tianqing Pharmaceutical\",\"Chipscreen Biosciences\",\"Patents\",\"SHA: 688321\"],\"articleSection\":[\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21681#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21681\",\"name\":\"Chipscreen's Epidaza Patent Faces Invalidation Request Review - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1601.png\",\"datePublished\":\"2025-01-16T09:13:05+00:00\",\"dateModified\":\"2025-01-16T09:13:53+00:00\",\"description\":\"China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection of intellectual property rights in the pharmaceutical sector.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21681\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1601.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1601.png\",\"width\":1080,\"height\":549,\"caption\":\"Chipscreen's Epidaza Patent Faces Invalidation Request Review\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21681#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chipscreen’s Epidaza Patent Faces Invalidation Request Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chipscreen's Epidaza Patent Faces Invalidation Request Review - Insight, China's Pharmaceutical Industry","description":"China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection of intellectual property rights in the pharmaceutical sector.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21681","og_locale":"en_US","og_type":"article","og_title":"Chipscreen's Epidaza Patent Faces Invalidation Request Review","og_description":"China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection of intellectual property rights in the pharmaceutical sector.","og_url":"https:\/\/flcube.com\/?p=21681","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-16T09:13:05+00:00","article_modified_time":"2025-01-16T09:13:53+00:00","og_image":[{"width":1080,"height":549,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1601.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21681#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21681"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chipscreen’s Epidaza Patent Faces Invalidation Request Review","datePublished":"2025-01-16T09:13:05+00:00","dateModified":"2025-01-16T09:13:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21681"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21681#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1601.png","keywords":["Cancer","Chia Tai Tianqing Pharmaceutical","Chipscreen Biosciences","Patents","SHA: 688321"],"articleSection":["Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21681#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21681","url":"https:\/\/flcube.com\/?p=21681","name":"Chipscreen's Epidaza Patent Faces Invalidation Request Review - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21681#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21681#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1601.png","datePublished":"2025-01-16T09:13:05+00:00","dateModified":"2025-01-16T09:13:53+00:00","description":"China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request filed by compatriot firm Chia Tai Tianqing relating to its Epidaza (chidamide) has been accepted for review by the China National Intellectual Property Administration (CNIPA). This development marks a significant legal milestone in the protection of intellectual property rights in the pharmaceutical sector.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21681#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21681"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21681#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1601.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1601.png","width":1080,"height":549,"caption":"Chipscreen's Epidaza Patent Faces Invalidation Request Review"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21681#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chipscreen’s Epidaza Patent Faces Invalidation Request Review"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1601.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21681"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21681\/revisions"}],"predecessor-version":[{"id":21684,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21681\/revisions\/21684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21682"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}